Biogen Inc. Furnishes and Full Year 2025 Results and 2026 Financial Guidance
Summary
On February 6, 2026, Biogen Inc. furnished a press release (via Ex. 99.1) announcing its results of operations and financial condition for the fourth quarter and full year ended December 31, 2025, and provided full year 2026 financial guidance. The company reported strong performance, with full year 2025 Non-GAAP diluted EPS exceeding its guidance range. - Total Revenue: $2.3 billion - Full Year 2025 Total Revenue: $9.9 billion - Full Year 2025 Non-GAAP Diluted EPS: $15.28 (exceeding guidance) - LEQEMBI global in-market sales: ~$134 million, up 54% year-over-year
Why It Matters
Investors should note Biogen's strong full year 2025 Non-GAAP diluted EPS of $15.28, which exceeded the upper end of its guidance range, signaling robust financial performance. The provision of full year 2026 financial guidance also offers forward-looking insights.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how BIIB traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View BIIB Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000875045
- Filing Date
- Friday, February 6, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive